Viral research using recombinant antigens from Sino Biological

Critical reagents in infectious disease research are recombinant antigens. They are commonly used in vaccine and therapeutic antibody development.

Image credit: Shutterstock.com/Corona Borealis Studio

ProVir™, the world’s largest recombinant viral antigen collection, has been independently developed by Sino Biological.

The collection features a comprehensive collection of influenza antigens, an exclusive coronavirus catalog and many other hard-to-find viral proteins such as Cytomegalovirus, Ebola, RSV and Zika. The ProVir™ viral antigen bank includes more than 1,000 antigens from 90 virus types/subtypes and 350 strains.

It has been widely used across the world for vaccine development, immunodiagnostic assay, therapeutic antibody evaluation and infectious disease research.

Recombinant SARS-CoV-2 variants

The B.1.351 variant, the P.1 variant, the B.1.1.7 variants and the most recent variant B.1.617 first detected in India are of central concern due to their high prevalence.

A panel of recombinant RBD/Spike and nucleocapsid protein variants have been developed by Sino Biological to evaluate the efficacy of vaccination and the antibodies.

Lineage RBD S-ECD N
B.1.617.2 40592-V08H90 40589-V08B16 40588-V07E29
B.1.617 40592-V08H88 40589-V08B12 40588-V07E20
B.1.1.7 40592-V08H82 40589-V08B6 40588-V07E8
P.1 40592-V08H86 40589-V08B8 40588-V07E11
B.1.351 40592-V08H85 40589-V08B7 40588-V07E9

Recombinant antigens for influenza vaccine strains

The ProVir™ collection also includes 630+ ME, NA and HA antigens from more than 250 strains of influenza viruses, including vaccine strains and the pandemic strains. Recombinant flu antigens from all WHO-recommended vaccine strains in recent years are offered by Sino Biological.

Strains HA NA NP Year
A/Cambodia/e0826360/2020 (H3N2) 40789-V08H
40789-V08H1
40784-V08B 40778-V08B 2021-2022
A/Victoria/2570/2019 (H1N1) 40787-V08H
40787-V08H1
40785-V08B 40774-V08B 2021-2022
A/Wisconsin/588/2019 (H1N1) 40787-V08H
40787-V08H1
40785-V08B 40774-V08B 2021-2022
B/Phuket/3073/2013 40498-V08B 40502-V07B 40500-V08B 2021-2022
2020-2021
2019-2020
2018-2019
2017-2018
2016-2017
2015-2016
B/Washington/02/2019 40722-V08H 40790-V08B 40755-V08B 2021-2022
2020-2021

Recombinant antigens for more infectious viruses

The ProVir™ collection includes antigens from a variety of viruses associated with many kinds of infectious diseases, ranging from common viruses such as HIV, HPV and RSV. It also includes viruses like Zika and Ebola.

Additionally, it features rare virus types like the vesicular stomatitis Indiana viruses and the Rift Valley fever.

Respiratory disease viruses

CMV EV-D68 HAdV-B HAdV-E HPIV-3
HPIV-4 HMPV-A HMPV-B RSV EBV
HCoV-229E HCoV-HKU1 HCoV-NL63 HCoV-OC43 MERS-CoV
SARS-CoV

Hand, foot, and mouth disease viruses

EV-71 CV

Blood-borne disease viruses

HIV HBV HCV

Tropical & vector-borne diseases

DENV CHIKV WNV ZIKV RVFV

More disease viruses

EBOV HTNV HeV VSIV PCV2
SIV CyCMV DcCoV

About Sino Biological Inc.

Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development.

All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements.

In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.

Sino Biological's core business

Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world.

All of their products are independently developed and produced. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.

Their product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for them to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jul 1, 2021 at 3:19 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2021, July 01). Viral research using recombinant antigens from Sino Biological. News-Medical. Retrieved on August 01, 2021 from https://www.news-medical.net/whitepaper/20210629/Viral-research-using-recombinant-antigens-from-Sino-Biological.aspx.

  • MLA

    Sino Biological Inc.. "Viral research using recombinant antigens from Sino Biological". News-Medical. 01 August 2021. <https://www.news-medical.net/whitepaper/20210629/Viral-research-using-recombinant-antigens-from-Sino-Biological.aspx>.

  • Chicago

    Sino Biological Inc.. "Viral research using recombinant antigens from Sino Biological". News-Medical. https://www.news-medical.net/whitepaper/20210629/Viral-research-using-recombinant-antigens-from-Sino-Biological.aspx. (accessed August 01, 2021).

  • Harvard

    Sino Biological Inc.. 2021. Viral research using recombinant antigens from Sino Biological. News-Medical, viewed 01 August 2021, https://www.news-medical.net/whitepaper/20210629/Viral-research-using-recombinant-antigens-from-Sino-Biological.aspx.

Other White Papers by this Supplier